3SBio Inc. Acquires Worldwide Rights to Pegsiticase for $6.35M

by Benzinga Staff
November 29, 2010 7:27 AM | 9 seconds read |
3SBio Inc. SSRX today announced that is has acquired worldwide rights of pegsiticase for all indications from EnzymeRx for a total consideration of US$6.25 million.
Market News and Data brought to you by Benzinga APIs

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Comments
Posted In: NewsM&ABiotechnologyHealth Care
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!